Source - RNS
RNS Number : 7664Y
Eco Animal Health Group PLC
11 September 2020
 

 

 

ECO Animal Health Group plc

("ECO" or the "Group")

(AIM: EAH)

 

NOTICE OF RESULTS FOR YEAR ENDED 31 MARCH 2020

 

ECO Animal Health Group plc (the "Group") announces that the Group intends to publish its annual audited accounts for the year ended 31 March 2020 during November and prior to 30 November 2020.

The Group was granted an up to two month extension to the publication timetable in order to manage additional difficulties arising from auditing the Group's international operations during the Covid-19 pandemic restrictions and against the backdrop of new auditors and new accounting policies adopted at the time of the most recent interim report.

Consistent with the Government extension to the deadline for filing accounts at Companies House, the deadline for holding an Annual General Meeting has also been extended and must now be held before 31 December 2020.  As is customary, the Group will give notice of the date for holding the AGM at the same time as publishing its annual audited accounts.

The Group provided a Trading update on 10 June 2020, noting that the Group had seen strong financial performance in the year ended 31 March 2020 and that Revenue and EBITDA were expected to be significantly ahead of market expectations.  A current year trading update will be provided after the half year ending on 30 September 2020.

 

Contacts:  

ECO Animal Health Group plc

Marc Loomes (CEO)

Christopher Wilks (CFO)

 

020 8447 8899

 

IFC Advisory

Graham Herring

Zach Cohen

 

020 3934 6630

 

N+1 Singer (Nominated Adviser & Joint Broker)

Mark Taylor

Peter Steel

Alex Bond

 

020 7496 3000

Peel Hunt LLP (Joint Broker)

James Steel

Dr Christopher Golden

020 7418 8900

 

ECO Animal Health Group plc ("ECO" or "the "GROUP") researches, develops and commercialises products for livestock. Our business strategy is to generate shareholder value by achieving the maximum sales potential from the existing product portfolio whilst investing in Research and Development ("R&D") for new products, particularly vaccines, and seeking to in-license new products.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NORBGGDCRGBDGGB
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.